Home › Funds › Blue Owl Capital Holdings LP › AQST
Blue Owl Capital Holdings LP position in AQST
AQUESTIVE THERAPEUTICS INC · Health Care
Blue Owl Capital Holdings LP reported holding 1,390,632 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.4M, representing 1.21% of its reported portfolio and ranking #14 among its reported holdings. Blue Owl Capital Holdings LP has disclosed AQST holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Blue Owl Capital Holdings LP's AQST position evolved
Blue Owl Capital Holdings LP first disclosed a stake in AQST in Q1 2024 at 875,000 shares (US$3.7M). The position peaked in Q3 2025 at 1,250,000 shares, worth US$7.0M. Across 11 filings, Blue Owl Capital Holdings LP increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,390,632 shares valued at US$6.4M — an increase of 447,700 shares quarter over quarter.. Notable position changes include a 58% trim in Q4 2025 (shares fell 36% over the following quarter), a 157% increase in Q1 2026 (shares were roughly flat over the following quarter), a 47% increase in Q3 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 875.00K | $3.73M | New |
| Q2 2024 | 1.14M | $2.96M | Add |
| Q3 2024 | 1.23M | $6.10M | Add |
| Q4 2024 | 900.00K | $3.20M | Reduce |
| Q1 2025 | 920.00K | $2.67M | Add |
| Q2 2025 | 920.00K | $3.05M | Hold |
| Q3 2025 | 1.25M | $6.99M | Add |
| Q4 2025 | 525.00K | $3.39M | Reduce |
| Q1 2026 | 1.35M | $5.59M | Add |
| Q2 2026 | 942.93K | $3.92M | Reduce |
| Q3 2026 | 1.39M | $6.44M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in AQST — the largest reported positions include Bratton Capital Management, L.P. (US$45.4M), Samsara BioCapital, LLC (US$10.4M), Propel Bio Management, LLC (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Bratton Capital Management, L.P. 9.81M sh · $45.42M · Q3 2026
- Samsara BioCapital, LLC 2.50M sh · $10.40M · Q2 2026
- Propel Bio Management, LLC 278.72K sh · $8.61M · Q3 2026
- Sio Capital Management, LLC 1.49M sh · $6.18M · Q2 2026
- DAFNA Capital Management LLC 645.91K sh · $2.69M · Q2 2026
- Everstar Asset Management, LLC 611.94K sh · $2.55M · Q2 2026
- Bracebridge Capital, LLC 459.22K sh · $1.91M · Q2 2026
More on Blue Owl Capital Holdings LP
FAQ
How long has Blue Owl Capital Holdings LP held AQST?
Blue Owl Capital Holdings LP has disclosed AQST holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Blue Owl Capital Holdings LP's current position in AQST?
As of Q3 2026, Blue Owl Capital Holdings LP holds 1.39M shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $6.44M, representing 1.21% of its reported portfolio and ranking #14.
Has Blue Owl Capital Holdings LP been buying or selling AQST?
In the latest 13F filing (Q3 2026), Blue Owl Capital Holdings LP increased its position in AQST. The position peaked in Q3 2025 at 1.25M shares.
Which other funds hold AQST?
Other major institutional holders of AQST include Bratton Capital Management, L.P., Samsara BioCapital, LLC, Propel Bio Management, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.